Skip to content

Study · Non-randomized trial · n = 166 · 2015

3 results

Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.

Schernthaner G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B

Diabetes, obesity & metabolism8 May 2015Cited by 4 (Europe PMC)

PMID25846577 (opens in a new tab)DOI10.1111/dom.12471 (opens in a new tab)PepBankPUB-25846577
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In T2DM on metformin/glimepiride, add-on exenatide reduced HbA1c from baseline at 130 weeks.

    In plain wordsIn diabetes on metformin/glimepiride, adding exenatide reduced HbA1c compared with baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c after exenatide addition
    Study

    n = 166

    Comparator
    metformin + glimepiride before exenatide addition
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 130 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.35%
    130 weeks
    HbA1c change SD
    0.89%
    130 weeks
    HbA1c change
    −3.8 mmol/mol
    130 weeks
    HbA1c change SD
    9.7 mmol/mol
    130 weeks

    Source sentences

    Summary
    Add-on exenatide twice daily after metformin + glimepiride significantly reduced HbA1c levels: mean [standard deviation (s.d.)] change from baseline -0.35 (0.89)% [-3.8 (9.7) mmol/mol] and BMI: mean (s.d.) change from baseline -0.82 (1.9) kg/m(2) at 130 weeks,
  2. 02HumanNon-randomized trialEfficacy outcome

    In T2DM on metformin/glimepiride, add-on exenatide reduced BMI from baseline at 130 weeks.

    In plain wordsIn diabetes on metformin/glimepiride, adding exenatide reduced BMI compared with baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBMI after exenatide addition
    Study

    n = 166

    Comparator
    metformin + glimepiride before exenatide addition
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 130 weeksAs given in this study (human).

    Measurements

    BMI change
    −0.82 kg/m(2)
    130 weeks
    BMI change SD
    1.9 kg/m(2)
    130 weeks

    Source sentences

    Summary
    Add-on exenatide twice daily after metformin + glimepiride significantly reduced HbA1c levels: mean [standard deviation (s.d.)] change from baseline -0.35 (0.89)% [-3.8 (9.7) mmol/mol] and BMI: mean (s.d.) change from baseline -0.82 (1.9) kg/m(2) at 130 weeks,
  3. 03HumanNon-randomized trialSafety outcome

    In T2DM on metformin/glimepiride, adding exenatide slightly increased documented symptomatic hypoglycaemia rates from baseline.

    In plain wordsIn diabetes on metformin/glimepiride, adding exenatide slightly increased symptomatic low blood sugar events compared with baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHypoglycaemia after exenatide addition
    Study

    n = 166

    Comparator
    metformin + glimepiride before exenatide addition
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 130 weeksAs given in this study (human).

    Measurements

    hypoglycaemia rate ratio
    1.49 ratio
    after versus before exenatide addition

    Source sentences

    Summary
    with a slightly increased rate of documented symptomatic hypoglycaemia from metformin + glimepiride (ratio 1.49).
    1 context sentence
    Summary · context
    Add-on exenatide twice daily after metformin + glimepiride significantly reduced HbA1c levels:

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00359762

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

AstraZenecan = 1,029Sept 2006 to Mar 2011

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 15 Sept 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.